+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tarceva"

Lung Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Lung Cancer Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
Lung Cancer Therapeutics: Global Markets - Product Thumbnail Image

Lung Cancer Therapeutics: Global Markets

  • Report
  • November 2018
  • 161 Pages
  • Global
From
Tarceva - Product Thumbnail Image

Tarceva

  • Report
  • August 2018
  • 25 Pages
  • Global
From
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC) - Product Thumbnail Image

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

  • Report
  • April 2021
  • 191 Pages
  • Global
Tarceva - API Insight, 2022 - Product Thumbnail Image

Tarceva - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Tarceva- Drug Insight, 2019 - Product Thumbnail Image

Tarceva- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Tarceva is a drug used to treat non-small cell lung cancer (NSCLC). It is a targeted therapy that works by blocking the epidermal growth factor receptor (EGFR) on the surface of cancer cells. This prevents the cancer cells from growing and spreading. Tarceva is used in combination with chemotherapy and other treatments to improve the effectiveness of the treatment. It is also used as a maintenance therapy to help keep the cancer from coming back. Tarceva is approved for use in the United States, Europe, and other countries. Tarceva is a part of a larger market of drugs used to treat lung cancer. Other drugs in this market include chemotherapy drugs, immunotherapy drugs, and targeted therapies. These drugs are used in combination with each other to provide the best possible outcome for patients. Companies in the Tarceva market include AstraZeneca, F. Hoffmann-La Roche, and Eli Lilly. Show Less Read more